Skip to main content

Remote Job Finders (RJF)

Webinar: Are We There Yet? Surviving and Thriving in the Never-ending Biotech Downturn

BioSpace sits down with four NextGen companies that are thriving despite a multi-year down period. You will hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out. Watch now.

Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director Vinay Prasad reveal new COVID-19 vaccine strategy following Novavax approval; ODAC underway after chaotic planning; more.

Evolving Market Pressures Force Biopharma Companies to Cut Assets Early

From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led firms to make tough pipeline decisions early in the development process. The result may be costly for all of us.

Southeast’s Life Sciences Scene Heats Up With Job, Business Growth

Nine states in the Southeast showed growth in bioscience employment and establishments from 2019 to 2023, according to 2024 data from BIO and TEConomy Partners. NCBiotech and Bexion executives discuss the area and the pros and cons of setting up shop far from major hubs.
Scroll to top